Miss Yan

Miss Yan

OVERVIEW

Name: Miss Yan
Diagnosis: Diabetes
Gender: Female
Country: China

Treatment: ve injections of mesenchymal cells, (MSC)

HISTORY:

Miss Yan, an 18-year-old female, was admitted to Puhua International Hospital for Cellular Treatment of Type-1 Diabetes. Miss Yan was diagnosed with Type-1 Diabetes 5 years prior to admission, with typical diabetic symptoms: thirst, increased hunger, frequent urination, and loss of weight. She began to have insulin treatment at a local hospital. She once had an episode of ketoacidosis (DKA) in 2009 and was subsequently hospitalized for treatment. In March 2010, she was treated in another Diabetes Hospital in Beijing. Her general condition was not good.

Two months before her arrival at PIH, Miss Chen (one of Miss Yan' friends who also had Type-1 Diabetes was treated at PIH), received great improvements with her Cellular Treatment (SCT).   After recommended by Miss Chen, Miss Yan and her mother decided to try cellular treatment at PIH.

Medical Condition before Cellular Treatment for Type-1 Diabetes:

Prior to Cellular Treatment (SCT), Miss Yan’s blood glucose tested at admission was relatively stable, with fasting plasma blood glucose controlled at a level of 6.7-9.4mmol/L and postprandial blood glucose at a level of 6.2-9.4mmol/L. Her glycosylated hemoglobin (HbA1C) was high, at 11.6, which meant that her blood sugar was under poor control during the previous three months. Her eyelids were swollen and edema was noted at her both feet on admission. Her mental status was not positive, and she felt fatigued. Type B ultrasound of abdomen revealed that there was abdominal fluid.

In order to control her blood glucose, she usually used 26 Units of insulin per day: 5 Units of regular insulin before breakfast, 4 Units of regular insulin before lunch, 5 Units of regular insulin before supper, and 12 Units of insulin at bedtime.

Cellular Treatment for Type-1 Diabetes:

Five injections of mesenchymal cells, (MSC)

Medical Condition after Cellular Treatment for Type-1 Diabetes:

With the help of cellular treatment, Miss Yan’s condition improved gradually. Cellular treatment helped her with not only her blood glucose, but also other symptoms. Her fasting plasma glucose was soon nearly normal; with a level of 5.0-6.4mmol/L. Her postprandial blood glucose was also nearly normal; with a level of 5.3-7.2mmol/L.  As said  herself, she did not want to do anything before the treatment, because she always felt so tired. However, she was much more energetic after therapy. Her eyelids were not swollen anymore, and the edema of her feet had resolved.

With the better controlled blood glucose, the insulin dosage was being reduced day-by-day. She just used18 Units of insulin in total per day at discharge, with a nearly normal level of blood glucose. She looks good in general, and enjoyed a good appetite.

Follow Up

After discharge, Miss Yan keeps in touch with PIH. Her blood glucose was controlled well and the insulin dosage was still being reduced. 15 days after her discharge, she told PIH by phone that she was down to 8 Units of insulin per day: 1 Units of regular insulin before breakfast, 1 Units of regular insulin before lunch, 2 Units of regular insulin before supper, and 4 Units of insulin at bedtime.

With reduced insulin dosage and stable blood glucose, Miss Yan and her mother were very pleased with the effect of Cellular Treatment.

On 23rd October 2010, the doctor adjusted the insulin dosage of Miss. Yan according to her blood glucose: she was stopped off of regular insulin. She was then using 4 Units of glargine insulin at bedtime. Her blood glucose was controlled well. Her fasting plasma glucose was nearly normal, with a level of 5.0-6.2mmol/L (reference value: 3.9-6.1mmol/L). Her postprandial blood glucose was at a level of 5.2-6.6mmol/L (reference value: <8.0mmol/L).

Miss. Yan stops using insulin

On 26th November 2010, two months after Cellular Treatment (SCT) for her Type-1 Diabetes, Patient Yan told PIH that she had totally stopped insulin injection.

Joomla SEO by AceSEF